09.19.2020
Other
$1,469,933.00
48 months
ICARUS –IBD: International study of COVID-19 Antibody Response Under Sustained immune suppression in Inflammatory Bowel Disease
IBD patients especially those receiving immune-suppressing infusion medications, are considered high-risk for COVID-19, but a systematic study to measure prevalence in the IBD community has not performed. This study will provide essential data that will inform guidance for IBD patients regarding the risk of COVID-19 infection and specific clinical and social factors that may be modified to decrease risk.